$JNJ

Duato Joaquin sold $32.2M of JNJ

Duato Joaquin (CEO and Chairman of the Board) sold 123,291 shares of JOHNSON & JOHNSON (JNJ) at an average of $261.17 ($261.00–$262.00, $32.20M total) across 2 trades on 2026-08-13.

Original reporting
SEC EDGAR · Duato Joaquin
Published Aug 14, 2026, 8:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$JNJ
Neutral
low confidence
Mentioned
$JNJ
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$JNJNeutralLow
01

Why it matters

A CEO open-market sale of roughly $32.2M can create short-term negative optics, but it does not change fundamentals absent accompanying guidance, legal, or operational news.

02

Market read

Traders may monitor for follow-on insider activity or correlate with price/volume, but the filing does not provide new business information.

03

What to watch

No 10b5-1 plan is stated, but the filing alone does not reveal tax, estate, or diversification context, limiting inference quality.

Relevance 7/10Novelty 5/10Timing: filed 2026-08-14, sale executed 2026-08-13

Background

The article is an SEC Form 4 insider transaction disclosure for Johnson & Johnson.

Company-level read

Ticker impact

$JNJNeutralLow confidence
Context

SEC Form 4 shows CEO and Chairman Duato Joaquin sold 123,291 shares of JNJ for about $32.2M on 2026-08-13.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than earnings or guidance-driven.

Evidence & confidence

The filing is primary-source and material in size, but insider sales are often pre-planned or diversified and the text provides no new operational or financial information.

Market effects

No direct sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

The sale may reflect diversification or liquidity needs and does not necessarily signal reduced confidence, especially without evidence of a related negative event.

Key entities

  • Johnson & Johnson

    Subject of the Form 4 insider sale disclosure.

  • Duato Joaquin

    CEO and Chairman of the Board who sold shares via open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$JNJMedAI 8/10

Johnson & Johnson outlook: bull and bear cases after Q3 earnings

Johnson & Johnson (JNJ) reported Q3 adjusted EPS of $2.59, beating estimates. The company raised operational sales-growth guidance to 6.7%–7.1% and maintained $21B in free cash flow. Bulls highlight pipeline momentum and technical support, while bears point to margin compression and MedTech weakness. The stock trades at $259.80, with analysts' target upside at 9.8%.

$JNJMedAI 8/10

Johnson & Johnson CFO taps internal investment for medtech growth

Johnson & Johnson CFO Joseph Wolk stated the company will use internal investments to drive medtech growth, aiming for double-digit growth by 2030. Q3 medtech sales rose 2.5%, below expectations, but innovative medicine sales offset this. J&J reported $25B in net sales, up 6%, but net earnings dropped 96% YoY due to M&A and litigation costs. The company expects $101B-$101.4B in 2026 sales.

$JNJHigh

Johnson & Johnson PR: Tylenol Recall to Talc Settlement

Johnson & Johnson (J&J) announced a $5.5B talc settlement on July 27, 2026, covering 76,000 ovarian cancer claims. The company expects to pay $3B in 2027, with the total potentially reaching $7B. J&J is also separating its orthopaedics business, DePuy Synthes, with a 2025 sales of $9.3B. Additionally, Kenvue, J&J's consumer health spinoff, was acquired by Kimberly-Clark for $48.7B in 2025. J&J's 2025 sales outlook was $93.5B to $93.9B.

$JNJHighAI 8/10

J&J posts weak medical device sales, shares fall

Johnson & Johnson reported medical device sales of $8.6B, missing estimates of $8.71B, citing geopolitical issues. Shares fell 6%. CFO Joe Wolk attributed weakness to Middle East conflict, European austerity, and China pricing. The company raised its full-year sales forecast to $101.2B and adjusted earnings to $11.10 per share. Pharmaceutical sales rose 7.7% to $16.76B, with Tremfya sales up 68% to $2.4B.